Clinical Trials | October 01, 2025
Winrevair cuts risk of PAH progression by 76% in phase 3 Hyperion trial
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Goyal reaffirmed the government’s commitment to facilitating market access, reducing trade barriers, and ensuring that Indian exporters remain globally competitive
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Subscribe To Our Newsletter & Stay Updated
